High Dose Antipsychotic Treatment (HDAT) – are you following the guidelines?
High Dose Antipsychotic Treatment (HDAT) is a term many of us are familiar with but are you confident in it’s use, need and subsequent monitoring requirements? Are the multidisciplinary team aware of the individual roles and responsibilities associated with prescribing above 100% BNF doses for antipsychotic therapy?
Some common questions asked are:
- What is HDAT?
- Why do I need to be aware of HDAT?
- What do I monitor and when?
- Is there rationale for HDAT?
- What is the evidence base for HDAT?
We have recently updated our Ashtons High Dose Antipsychotic Treatment (HDAT) training seminar which is one of several educational seminars available to our hospitals as part of the annual training allocation. This is usually delivered face to face to up to 20 members of the team including nurses, doctors or healthcare workers. Due to COVID-19 restrictions we are also able to offer this training online via Microsoft Teams or Zoom.
Updates to our seminar include:
- How the appropriate effective doses are established by drug companies
- Familiarity with using the BNF and Summary of Product Characteristics (SPC) to identify maximum licensed doses
- Why HDAT?
- In depth look at the effectiveness of Clozapine and importance of timely initiation
- HDAT monitoring requirements
- Familiarity with the new Ashtons High Dose Antipsychotic Treatment (HDAT) monitoring form
- Questions and Answers so your knowledge can be tested
To book a seminar, please liaise with your Ashtons Visiting Pharmacist.
Our new HDAT monitoring form – what has changed?
Our monitoring form is now double-sided allowing suitable use for long stay patients as well as a more acute setting. It can be ordered online via order code (HDAT1) or contact customer services on 0345 222 3550 or email email@example.com